Patents by Inventor Daniel J. Kerkman
Daniel J. Kerkman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080181883Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.Type: ApplicationFiled: April 1, 2008Publication date: July 31, 2008Inventors: Raymond P. Zinkowski, Daniel J. Kerkman, Russel E. Kohnken, John F. DeBernardis, Peter Davies
-
Patent number: 6864062Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.Type: GrantFiled: December 12, 2001Date of Patent: March 8, 2005Assignee: Molecular Geriatrics CorporationInventors: Raymond P. Zinkowski, Daniel J. Kerkman, Russell E. Kohnken, John F. DeBernardis, Peter Davies
-
Publication number: 20030113896Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detectiing human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.Type: ApplicationFiled: December 12, 2001Publication date: June 19, 2003Inventors: Raymond P. Zinkowski, Daniel J. Kerkman, Russell E. Kohnken, John F. DeBernardis, Peter Davies
-
Publication number: 20020002270Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.Type: ApplicationFiled: June 16, 1999Publication date: January 3, 2002Inventors: RAYMOND P. ZINKOWSKI, DANIEL J. KERKMAN, RUSSELL E. KOHNKEN, JOHN F. DEBERNARDIS, PETER DAVIES
-
Patent number: 5559144Abstract: Compounds of the structure ##STR1## where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or --NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzo[b]furyl, thienyl, or benzo[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.Type: GrantFiled: May 5, 1995Date of Patent: September 24, 1996Assignee: Abbott LaboratoriesInventors: Dee W. Brooks, Andrew O. Stewart, Daniel J. Kerkman, Pramila A. Bhatia, Anwer Basha, Jonathan G. Martin
-
Patent number: 5476873Abstract: Compounds of the structure ##STR1## where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or --NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzo[b]furyl, thienyl, or benzo[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.Type: GrantFiled: April 19, 1994Date of Patent: December 19, 1995Assignee: Abbott LaboratoriesInventors: Dee W. Brooks, Andrew O. Stewart, Daniel J. Kerkman, Pramila A. Bhatia, Anwer Basha, Jonathan G. Martin
-
Patent number: 5389638Abstract: The present invention provides a tetrahydroisoquinoline compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof which is an antagonist for alpha-2 adrenoreceptors and/or which inhibits biogenic amine uptake.Type: GrantFiled: September 10, 1993Date of Patent: February 14, 1995Assignee: Abbott LaboratoriesInventors: John F. DeBernardis, Daniel J. Kerkman, Robert E. Zelle, William McClellan
-
Patent number: 5326776Abstract: Compounds are disclosed having the formula: ##STR1## wherein the substituents are defined herein. The compounds of the invention are angiotensin II receptor antagonists.Type: GrantFiled: February 24, 1993Date of Patent: July 5, 1994Assignee: Abbott LaboratoriesInventors: Martin Winn, Biswanath De, Thomas M. Zydowsky, Daniel J. Kerkman, John F. DeBernardis, Saul H. Rosenberg, Kazumi Shiosaki, Fatima Z. Basha, Kenneth P. Spina, Thomas W. von Geldern, Steven Boyd, Diane M. Yamamoto, Anthony K. L. Fung
-
Patent number: 5250548Abstract: Compounds are disclosed having the formula: ##STR1## The compounds of the invention are angiotensin II receptor antagonists.Type: GrantFiled: March 2, 1992Date of Patent: October 5, 1993Assignee: Abbott LaboratoriesInventors: Martin Winn, Biswanath De, Thomas M. Zydowsky, Daniel J. Kerkman, John F. DeBernardis, Saul H. Rosenberg, Kazumi Shiosaki, Fatima Z. Basha, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Steven Boyd, Diane M. Yamamoto, Anthony K. L. Fung
-
Patent number: 5210206Abstract: The present invention relates to a process for the preparation of a compound of the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, loweralkyl, loweralkoxy-substituted loweralkyl, lower alkenyl, lower alkynyl, cycloalkyl and cycloalkylalkyl; R.sub.2 is selected from the group consisting of hydrogen, loweralkyl, loweralkoxy-substituted loweralkyl, halogen and loweralkoxy; R.sub.3 is selected from hydrogen, loweralkyl, and halogen; R* and R** are independently selected from loweralkyl and P.sub.1 is hydrogen or an nitrogen-protecting group; or an acid addition salt thereof.Type: GrantFiled: January 10, 1992Date of Patent: May 11, 1993Assignee: Abbott LaboratoriesInventors: Howard E. Morton, Biswanath De, Daniel J. Kerkman
-
Patent number: 5185363Abstract: Substituted phenyl, naphthyl, and thienyl N-hydroxy urea compounds form a class of potent inhibitors of 5- and 12-lipoxygenase and are thus useful compounds in the treatment of inflammatory disease states where leukotrienes and other products of lipoxygenase enzyme activity are implicated.Type: GrantFiled: September 30, 1991Date of Patent: February 9, 1993Assignee: Abbott LaboratoriesInventors: Dee W. Brooks, Daniel J. Kerkman, Jonathan G. Martin, Andrew O. Stewart, James B. Summers
-
Patent number: 4618683Abstract: Disclosed herein are tetrahydro-benzo[e]isoindolines represented by the formula ##STR1## wherein R, R.sub.1 and R.sub.2 are independently selected from hydrogen, loweralkyl of 1 to 4 carbon atoms, hydroxy, loweralkoxy of 1 to 3 carbon atoms, allyloxy, benzyloxy, benzoyloxy, thiomethyl, halo, ##STR2## wherein t is 0 or 1, n is 0 to 5 and R.sub.11 and R.sub.14 are independently selected from hydrogen, halo, hydroxy, loweralkyl of 1 to 4 carbon atoms, loweralkoxy of 1 to 3 carbon atoms or amino; orR and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen and the proviso that two of R, R.sub.1, or R.sub.2 must be other than methoxy in the 7 and 8 positions when the remaining one of R, R.sub.1 or R.sub.2 is hydrogen; andR.sub.Type: GrantFiled: November 20, 1984Date of Patent: October 21, 1986Assignee: Abbott LaboratoriesInventors: John F. DeBernardis, Daniel J. Kerkman, William J. McClellan